FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's CancerA2A PharmaMay 22, 20230 min read
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
A2A / Daewoong Pharmaceutical Oncology Agreement A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...
A2A Appoints New AdvisorsDr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE
Comments